JP2023550740A5 - - Google Patents
Info
- Publication number
- JP2023550740A5 JP2023550740A5 JP2023529980A JP2023529980A JP2023550740A5 JP 2023550740 A5 JP2023550740 A5 JP 2023550740A5 JP 2023529980 A JP2023529980 A JP 2023529980A JP 2023529980 A JP2023529980 A JP 2023529980A JP 2023550740 A5 JP2023550740 A5 JP 2023550740A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- cancer
- days
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115398P | 2020-11-18 | 2020-11-18 | |
| US63/115,398 | 2020-11-18 | ||
| US202163140125P | 2021-01-21 | 2021-01-21 | |
| US63/140,125 | 2021-01-21 | ||
| US202163184295P | 2021-05-05 | 2021-05-05 | |
| US63/184,295 | 2021-05-05 | ||
| US202163275480P | 2021-11-04 | 2021-11-04 | |
| US63/275,480 | 2021-11-04 | ||
| PCT/IB2021/060679 WO2022107027A1 (en) | 2020-11-18 | 2021-11-18 | Administration of sting agonist, checkpoint inhibitors, and radiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550740A JP2023550740A (ja) | 2023-12-05 |
| JP2023550740A5 true JP2023550740A5 (https=) | 2024-11-26 |
Family
ID=79287967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529980A Pending JP2023550740A (ja) | 2020-11-18 | 2021-11-18 | Ｓｔｉｎｇアゴニスト、チェックポイント阻害剤、及び放射線の投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240335464A1 (https=) |
| EP (1) | EP4247385A1 (https=) |
| JP (1) | JP2023550740A (https=) |
| KR (1) | KR20230110254A (https=) |
| AU (1) | AU2021383424A1 (https=) |
| CA (1) | CA3196529A1 (https=) |
| MX (1) | MX2023005695A (https=) |
| TW (1) | TW202233206A (https=) |
| WO (1) | WO2022107027A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026053158A1 (en) * | 2024-09-06 | 2026-03-12 | Takeda Pharmaceutical Company Limited | Dazostinag or conjugates thereof for treatment of neuroendocrine neoplasms |
| WO2026053159A1 (en) * | 2024-09-06 | 2026-03-12 | Takeda Pharmaceutical Company Limited | Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
| PE20210255A1 (es) * | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| AU2017378782A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| RU2020109328A (ru) * | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| WO2020049534A1 (en) * | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
| IL287938B2 (en) * | 2019-05-10 | 2025-07-01 | Takeda Pharmaceuticals Co | Antibody-drug conjugates |
| TW202116330A (zh) * | 2019-07-09 | 2021-05-01 | 日商武田藥品工業股份有限公司 | Sting 促效劑及檢查點抑制劑之投與 |
-
2021
- 2021-11-18 JP JP2023529980A patent/JP2023550740A/ja active Pending
- 2021-11-18 CA CA3196529A patent/CA3196529A1/en active Pending
- 2021-11-18 MX MX2023005695A patent/MX2023005695A/es unknown
- 2021-11-18 WO PCT/IB2021/060679 patent/WO2022107027A1/en not_active Ceased
- 2021-11-18 AU AU2021383424A patent/AU2021383424A1/en active Pending
- 2021-11-18 TW TW110142964A patent/TW202233206A/zh unknown
- 2021-11-18 EP EP21840113.1A patent/EP4247385A1/en active Pending
- 2021-11-18 KR KR1020237015686A patent/KR20230110254A/ko active Pending
- 2021-11-18 US US18/253,425 patent/US20240335464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Groot et al. | CDK4/6 inhibition in early and metastatic breast cancer: A review | |
| ES2870805T3 (es) | Tratamiento combinado de cáncer | |
| JP2019532051A5 (https=) | ||
| JP2018508516A5 (https=) | ||
| JP2021512121A5 (https=) | ||
| Biau et al. | Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma | |
| CN105452258B (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| JP2021520406A5 (https=) | ||
| Haddad et al. | Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer | |
| ES2688809T3 (es) | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer | |
| JP2023550740A5 (https=) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| Wang et al. | Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment | |
| JP2023102786A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| Kim et al. | Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer | |
| FI3888647T3 (fi) | Ezh1/2-kaksoisestäjän sisältävä farmaseuttinen koostumus käytettäväksi yhdistelmälääkkeenä | |
| JP2014512362A5 (https=) | ||
| JP2023531090A5 (https=) | ||
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| JP6449537B2 (ja) | 抗腫瘍剤、及び、抗腫瘍用キット | |
| JP2022520981A (ja) | 経口投与されるジオキソランヌクレオチドを抗ｐｄ１又は抗ｐｄｌ１モノクローナル抗体と組み合わせて用いる肝臓がんの治療法 | |
| Mortimer et al. | Safety considerations for use of bone-targeted agents in patients with cancer | |
| JP2024520307A5 (https=) | ||
| TW202143973A (zh) | 用於治療ＰＲＣ２介導的疾病或障礙的Ｎ—（（５—氟—２，３—二氫苯并呋喃—４—基）甲基）—８—（２—甲基吡啶—３—基）—［１，２，４］三唑并［４，３—ｃ］嘧啶—５—胺或其藥學上可接受的鹽之給藥方案 |